Catalent, novo nordisk and european commission

Novo Holdings set to win EU nod for $16.5 billion Catalent deal, source says
Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug maker Catalent, a person with direct knowledge of the matter said on Friday,
Catalent gains on reports it's likely to be granted EU approval for Novo Holdings deal (update)
The European Commission is expected to give unconditional approval for the $16.5 billion purchase of Catalent (NYSE: CTLT) as the parties haven't been asked to attend a "state of play" meeting, according to an MLex report that circulated on Friday.
Novo slated to win EU approval for Catalent takeover, Reuters says
Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is slated to received unconditional EU antitrust approval for its proposed
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent , people familiar with the matter said.
Catalent gains on report it's likely to be granted EU approval for Novo Holdings deal
Catalent (NYSE:CTLT) rose 2% amid a report that the European Union's antitrust regulator will likely grant approval for its planned sale to Novo Holdings, the parent of Ozempic maker Novo Nordisk (NVO). The European Commission is expected to give ...
FierceBiotech12d
Novo Holdings, OrbiMed, Jeito lead $181M fundraise for ADC biotech
Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two ...
24/7 Wall St2d
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...
devdiscourse10d
Innovations and Challenges in Pharma: A Global Health Report
This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...
EU antitrust regulators set to okay $16.5 billion Novo Holdings, Catalent deal, source says
EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent, a ...